Metabolic Consequences of Solid Organ Transplantation

Area of Science:

• Transplant medicine
• Metabolic disease research
• Immunosuppression therapy

Background:

• Metabolic complications, including posttransplant diabetes, NAFLD, dyslipidemia, and obesity, affect over 50% of solid organ transplant recipients.
• These conditions are often exacerbated by immunosuppressive medications and post-transplant weight gain, shifting patients from a catabolic to an anabolic state.
• Both calcineurin inhibitors and mTOR inhibitors, common maintenance immunosuppressants, are associated with an increased risk of metabolic disease.

Purpose of the Study:

• To comprehensively review the molecular pathogenesis of post-transplant metabolic complications.
• To explore the potential genetic contributions (recipient and/or donor) to these metabolic conditions.
• To provide current evidence on prevention and management strategies for post-transplant metabolic complications and identify research gaps.

Main Methods:

• Comprehensive literature review of molecular pathogenesis.
• Analysis of genetic factors influencing metabolic complications.
• Synthesis of current evidence on prevention and therapeutic management.

Main Results:

• Metabolic complications significantly impact graft and patient survival, increasing risks of cardiovascular and cancer mortality.
• Emerging knowledge highlights molecular pathways and genetic predispositions.
• Current management strategies exist but require further research for optimization.

Conclusions:

• Post-transplant metabolic complications are prevalent and multifactorial, influenced by immunosuppression and genetics.
• These complications adversely affect long-term outcomes, including survival.
• Further translational research is crucial for improved prevention and therapeutic interventions.